Novavax (NVAX) Set to Announce Earnings on Monday

Novavax (NASDAQ:NVAX – Get Rating) will be releasing its earnings data after the market closes on Monday, May 9th. Analysts expect Novavax to post earnings of $3.33 per share for the quarter. Novavax has set its FY 2022 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Novavax (NASDAQ:NVAX – Get Rating) last announced its quarterly earnings results on Monday, February 28th. The biopharmaceutical company reported ($11.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.43) by ($9.75). The business had revenue of $222.20 million during the quarter, compared to analyst estimates of $331.79 million. Novavax had a negative net margin of 152.12% and a negative return on equity of 368.20%. The business’s revenue for the quarter was down 20.5% compared to the same quarter last year. During the same period last year, the company earned ($2.70) earnings per share. On average, analysts expect Novavax to post $23 EPS for the current fiscal year and $14 EPS for the next fiscal year.

NVAX traded up $1.68 on Tuesday, reaching $55.43. The company’s stock had a trading volume of 75,367 shares, compared to its average volume of 4,306,936. The stock has a 50 day moving average of $68.36 and a two-hundred day moving average of $116.68. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $4.23 billion, a price-to-earnings ratio of -2.36 and a beta of 1.59. Novavax has a fifty-two week low of $42.13 and a fifty-two week high of $277.80.

A number of brokerages recently issued reports on NVAX. Jefferies Financial Group assumed coverage on Novavax in a report on Tuesday, February 22nd. They issued a “buy” rating and a $198.00 price target for the company. Cowen assumed coverage on Novavax in a research note on Friday, January 21st. They issued an “outperform” rating and a $150.00 price objective for the company. HC Wainwright reduced their price objective on Novavax from $294.00 to $207.00 and set a “buy” rating for the company in a research note on Thursday, March 3rd. StockNews.com assumed coverage on Novavax in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Finally, B. Riley reduced their price objective on Novavax from $250.00 to $203.00 and set a “buy” rating for the company in a research note on Tuesday, April 26th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Novavax currently has an average rating of “Buy” and a consensus target price of $198.14.

In other news, Director James F. Young sold 12,500 shares of the company’s stock in a transaction that occurred on Thursday, March 31st. The stock was sold at an average price of $73.58, for a total transaction of $919,750.00. Following the completion of the sale, the director now owns 62,590 shares in the company, valued at $4,605,372.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.10% of the stock is owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the business. NEXT Financial Group Inc raised its position in Novavax by 207.5% in the fourth quarter. NEXT Financial Group Inc now owns 695 shares of the biopharmaceutical company’s stock worth $99,000 after acquiring an additional 469 shares in the last quarter. Toroso Investments LLC raised its position in Novavax by 17.9% in the fourth quarter. Toroso Investments LLC now owns 2,860 shares of the biopharmaceutical company’s stock worth $409,000 after acquiring an additional 434 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Novavax in the fourth quarter worth $515,000. Kingsview Wealth Management LLC raised its position in Novavax by 4.9% in the fourth quarter. Kingsview Wealth Management LLC now owns 3,943 shares of the biopharmaceutical company’s stock worth $564,000 after acquiring an additional 185 shares in the last quarter. Finally, JustInvest LLC raised its position in Novavax by 38.9% in the fourth quarter. JustInvest LLC now owns 4,815 shares of the biopharmaceutical company’s stock worth $689,000 after acquiring an additional 1,348 shares in the last quarter. Hedge funds and other institutional investors own 43.91% of the company’s stock.

About Novavax (Get Rating)

Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

Further Reading